Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.17%
#3 OpenEden OpenEden +11.49%
#4 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.67%
#5 Mantle Staked Ether Mantle Staked Ether +8.27%
#6 Palladium Network Palladium Network +7.82%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.66%
#8 Prom Prom +6.59%
#9 Zest Protocol Zest Protocol +6.19%
#10 EfficientFrontier EfficientFrontier +4.43%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
설정
언어
한국어
통화
USD
테마
Alligator Bioscience AB (publ) Alligator Bioscience AB (publ)

Alligator Bioscience AB (publ)

ATORX
주식 순위 #40436
Alligator Bioscience AB (publ) is a research-intensive biotechnology company... Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
주가
$0.00408798
마지막 동기화: 2026-08-13
시가총액
$147.44K
변동 (1일)
-0.54%
변동 (1년)
-99.15%
국가
SE
거래 Alligator Bioscience AB (publ) (ATORX)

카테고리

Healthcare
Alligator Bioscience AB (publ) (ATORX)의 P/E 비율
2026 기준 P/E 비율 TTM: 0
Alligator Bioscience AB (publ)의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 0입니다. 2026년 말 기준 P/E 비율은 0였습니다.
Alligator Bioscience AB (publ)의 P/E 비율 기록 (2026 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/E 비율
회사 P/E 비율 P/E 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.